High-throughput screening against ∼ 6.1 million structurally diverse, lead-like compounds to discover novel ROCK inhibitors for cerebral injury recovery

Molecular Diversity

Volumn 20, Issue 2, 2016, Pages 537-549

  Gong, Haoling ^a   Yuan, Zhicheng ^a   Zhan, Liping ^a  

^a AFFILIATED PEOPLE S HOSPITAL OF JIANGSU UNIVERSITY   (China)

Author keywords

Blood brain barrier; Cerebral injury; CNS; High throughput screening; Neuroregeneration; Rho associated protein kinase

Indexed keywords

RHO KINASE; RHO KINASE INHIBITOR; PROTEIN KINASE INHIBITOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN INJURY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOG; DRUG DETERMINATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; IC50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN INJURIES; CACO-2 CELL LINE; CHEMISTRY; ENZYME ACTIVE SITE; MDCK CELL LINE; METABOLISM; PRECLINICAL STUDY;

ANIMALS; BRAIN INJURIES; CACO-2 CELLS; CATALYTIC DOMAIN; DOGS; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MADIN DARBY CANINE KIDNEY CELLS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 84951757343     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-015-9650-y     Document Type: Article

References (35)

1. Schmandke A, Schmandke A, Strittmatter SM (2007) ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist 13:454–469. doi:10.1177/1073858407303611
2. Fujita Y, Yamashita T (2014) Axon growth inhibition by RhoA/ROCK in the central nervous system. Front Neurosci 8:338. doi:10.3389/fnins.2014.00338
3. Chen HF, Pan XL, Wang JW, Kong HM, Fu YM (2014) Protein–drug interactome analysis of SSRI-mediated neurorecovery following stroke. Biosystems 120:1–9. doi:10.1016/j.biosystems.2014.03.007
4. Mueller BK, Mack H, Teusch N (2005) Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4:387–398. doi:10.1038/nrd1719
5. Kubo T, Hata K, Yamaguchi A, Yamashita T (2007) Rho–ROCK inhibitors as emerging strategies to promote nerve regeneration. Curr Pharm Des 13:2493–2499. doi:10.2174/138161207781368657
6. Kubo T, Yamashita T (2007) Rho–ROCK inhibitors for the treatment of CNS injury. Recent Pat CNS Drug Discov 2:173–179. doi:10.2174/157488907782411738
7. Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Araie M (2013) Clinical study group phase 1 clinical trials of a selective Rho kinase inhibitor, K-115. JAMA Ophthalmol 131:1288–1295. doi:10.1001/jamaophthalmol.2013.323
8. Xin YL, Yu JZ, Yang XW, Liu CY, Li YH, Feng L, Chai Z, Yang WF, Wang Q, Jiang WJ, Zhang GX, Xiao BG, Ma CG (2015) FSD-C10: a more promising novel ROCK inhibitor than Fasudil for treatment of CNS autoimmunity. Biosci Rep 35:e00247. doi:10.1042/BSR20150032
9. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 23:3–25. doi:10.1016/S0169-409X(96)00423-1
10. Lee SK, Chang GS, Lee IH, Chung JE, Sung KY, No KT (2004) The PreADME: PC-based program for batch predication of ADME properties. In: Proceedings of the EuroQSAR 2004, Istanbul
11. Sahu M, Nerkar AG, Chikhale HU, Sawant SD (2015) In silico screening, synthesis and pharmacological screening of quinazolinones containing oxazepinone ring as NMDA receptor antagonists for anticonvulsant activity: part-I. J Young Pharm 7:21–27. doi:10.5530/jyp.2015.1.5
12. Irvine JD, Takahashi L, Lockhart K, Cheong J, Tolan JW, Selick HE, Grove JR (1999) MDCK (Madin–Darby canine kidney) cells: a tool for membrane permeability screening. J Pharm Sci 88:28–33. doi:10.1021/js9803205
13. Ames BN, Gurney EG, Miller JA, Bartsch H (1972) Carcinogens as frameshift mutagens: metabolites and derivatives of 2-acetylaminofluorene and other aromatic amine carcinogens. Proc Natl Acad Sci USA 69:3128–3132. doi:10.1073/pnas.69.11.3128
14. O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR (2011) Open Babel: an open chemical toolbox. J Cheminform 3:33. doi:10.1186/1758-2946-3-33
15. Mysinger MM, Shoichet BK (2010) Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model 50:1561–1573. doi:10.1021/ci100214a
16. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The protein data bank. Nucleic Acids Res 28:235–242. doi:10.1093/nar/28.1.235
17. Duan Y, Wu C, Chowdhury S, Lee MC, Xiong G, Zhang W, Yang R, Cieplak P, Luo R, Lee T, Caldwell J, Wang J, Kollman P (2003) A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantummechanical calculations. J Comput Chem 24:1999–2012. doi:10.1002/jcc.10349
18. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157–1174. doi:10.1002/jcc.20035
19. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926–935. doi:10.1063/1.445869
20. Darden T, York D, Pedersen L (1993) Particale mesh Ewald: and N.log(N) method for Ewald sums in large systems. J Chem Phys 98:10089–10092. doi:10.1063/1.464397
21. Ryckaert J, Ciccotti G, Berendsen HJC (1977) Numerical-integration of Cartesian equations of motion of a system with constraints—molecular dynamics of n-alkanes. J Comput Phys 23:327–341. doi:10.1016/0021-9991(77)90098-5
22. Homeyer N, Gohlke H (2012) Free energy calculations by the molecular mechanics Poisson–Boltzmann surface area method. Mol Inf 31:114–122. doi:10.1002/minf.201100135
23. Patel RA, Forinash KD, Pireddu R, Sun Y, Sun N, Martin MP, Schönbrunn E, Lawrence NJ, Sebti SM (2012) RKI-1447 is a potent inhibitor of the Rho-associated ROCK kinases with anti-invasive and antitumor activities in breast cancer. Cancer Res 72:5025–5034. doi:10.1158/0008-5472.CAN-12-0954
24. Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ (2012) Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). MedChemComm 3:699–709. doi:10.1039/c2md00320a
25. Shaw D, Hollingworth G, Soldermann N, Sprague E, Schuler W, Vangrevelinghe E, Duggan N, Thomas M, Kosaka T, Waters N, van Eis MJ (2014) Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension. Bioorg Med Chem Lett 24:4812–4817. doi:10.1016/j.bmcl.2014.09.002
26. Imamura F, Mukai M, Ayaki M, Akedo H (2000) Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase. Jpn J Cancer Res 91:811–816. doi:10.1111/j.1349-7006.2000.tb01018.x
27. Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, Seto M, Tsuruma K, Shimazawa M, Hara H (2013) Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol 170:341–351. doi:10.1111/bph.12277
28. Akama T, Dong C, Virtucio C, Sullivan D, Zhou Y, Zhang YK, Rock F, Freund Y, Liu L, Bu W, Wu A, Fan XQ, Jarnagin K (2013) Linking phenotype to kinase: identification of a novel benzoxaborole hinge-binding motif for kinase inhibition and development of high-potency rho kinase inhibitors. J Pharmacol Exp Ther 347:615–625. doi:10.1124/jpet.113.207662
29. Liu T, Lin Y, Wen X, Jorrisen RN, Gilson MK (2007) Binding DB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35:D198–D201. doi:10.1093/nar/gkl999
30. Wang R, Fang X, Lu Y, Wang S (2004) The PDBbind database: collection of binding affinities for protein–ligand complexes with known three-dimensional structures. J Med Chem 47:2977–2980. doi:10.1021/jm030580l
31. Meng EC, Shoichet BK, Kuntz ID (1992) Automated docking with grid-based energy evaluation. J Comp Chem 13:505–524. doi:10.1002/jcc.540130412
32. Irwin JJ, Shoichet BK (2005) ZINC—a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177–182. doi:10.1021/ci049714+
33. Ekins S, Nikolsky Y, Nikolskaya T (2005) Techniques: application of systems biology to absorption, distribution, metabolism, excretion and toxicity. Trends Pharmacol Sci 26:202–209. doi:10.1016/j.tips.2005.02.006
34. Liu J, Hu Y, Waller DL, Wang J, Liu Q (2012) Natural products as kinase inhibitors. Nat Prod Rep 29:392–403. doi:10.1039/c2np00097k
35. Palazzolo G, Horvath P, Zenobi-Wong M (2012) The flavonoid isoquercitrin promotes neurite elongation by reducing RhoA activity. PLoS One 7:e49979. doi:10.1371/journal.pone.0049979